Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to “$” and “U.S. dollars” mean U.S. dollars and all r ...

财务数据和关键指标变化 - 公司现金、现金等价物和受限现金总额为8900万美元,较2022年12月31日的9500万美元减少600万美元 [29] - 2023年上半年净亏损4600万美元,较2022年上半年的5400万美元减少800万美元,主要由于研发和销售费用的减少 [31][32] 各条业务线数据和关键指标变化 - 无具体披露 各个市场数据和关键指标变化 - 无具体披露 公司战略和发展方向及行业竞争 - 公司正在推进BALLI-01、NATHALI-01和AMELI-01三项临床试验,取得了积极进展 [15][17][22][25] - 公司正在开发基于TALEN和碱基编辑器的基因编辑技术,展现了强大的技术实力 [13] - 公司新任命Cecile Chartier为董事会董事,她将为公司带来丰富的细胞和基因治疗经验 [14] 管理层对经营环境和未来前景的评论 - 公司在极具挑战的市场环境下仍保持专注,致力于推进核心临床试验 [15] - 公司有信心通过自身的产品候选药物、技术和内部制造能力实现突破,在这一前景广阔的医疗科学领域处于领先地位 [35] 问答环节重要的提问和回答 问题1 **Yigal Nochomovitz 提问** 询问BALLI-01试验中UCART22的剂量安排 [38][40][41][42] 问题2 **Gena Wang 提问** 询问UCART22和其他ALL CAR-T产品的疗效持久性,以及公司在碱基编辑技术方面的规划 [46][48][49][50] 问题3 **Yanan Zhu 提问** 询问UCART20x22的首次人体试验数据预期、患者人群以及公司延长现金流的考虑 [57][59][60][63][65]

Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer Bing Wang - CFO Conference Call Participants Gena Wang - Barclays Bank Yigal Nochomovitz - Citigroup Anoumid Vaziri - Goldman Sachs Group Dev Prasad - Jefferies Hartaj Singh - Oppenheimer Jack Allen - Robert W. Baird & Co. Ingrid Gafanhao - Kempen Silvan Tuerkcan ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to “$” and “U.S. dollars” mean U.S. dollars and all referen ...

EXHIBIT 99.1 Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Mark Frattini - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Gena Wang - Barclays Andrea Tan - Goldman Sachs Jack Allen - Baird Hartaj Singh - Oppenheimer & Company David Dai - SMBC Yanan Zhu - Wells Fargo Securities Brooke Schuster - William Blair Silvan Tuer ...

EXHIBIT 99.1 Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 produc ...